Stout was engaged by a life sciences company to perform the related purchase price allocation as part of a $2 billion acquisition of a pharmaceuticals firm. Our scope of work involved valuing multiple reporting units as well as the underlying assets including over 25 on-market pharmaceuticals, 17 in-process research and development projects, customer relationships, real property, and personal property across the globe. We worked closely with senior finance officials during the due diligence process and delivered our analysis in an expedited time frame.